The Shipibo Ceremonial Use of Ayahuasca to Promote Well-Being: An Observational Study.

Shipibo ayahuasca herbal medicine quality of life traditional medicine well-being

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2021
Historique:
received: 30 10 2020
accepted: 21 04 2021
entrez: 24 5 2021
pubmed: 25 5 2021
medline: 25 5 2021
Statut: epublish

Résumé

Promoting well-being is one of the main goals to improve health in the world. We examined the well-being and quality of life over the course of one year in a sample that participated in an Indigenous Shipibo healing program where traditional healers work in a series of ayahuasca ceremonies. We also explored the role of decentering as a mediator of psychological well-being. Participants who attended the program responded to an online survey that included a Psychological Well-Being Scale; Oxford Happiness Questionnaire; The World Health Organization Quality of Life Spirituality, Religiousness, and Personal Beliefs scale; the WHO Quality of Life-BREF scale; and Decentering scale. Baseline (T0) and postassessment (T1) were completed by 200 individuals. Of these, 101 completed the follow-up assessment at three months (T2), 91 at 6 months (T3), and 94 at 12 months follow-up (T4) after leaving the center. ANOVA test was performed in a representative subsample to control the passing of time two months before attending the program (T-1). Pearson's test was performed to examine the relationship between psychological well-being and decentering during the period of T0 and T1. A significant increase was observed in all the scales at all time points (

Identifiants

pubmed: 34025402
doi: 10.3389/fphar.2021.623923
pii: 623923
pmc: PMC8131827
doi:

Types de publication

Journal Article

Langues

eng

Pagination

623923

Informations de copyright

Copyright © 2021 Gonzalez, Cantillo, Perez, Carvalho, Aronovich, Farre, Feilding, Obiols and Bouso.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Psychopharmacol. 2016 Feb;36(1):77-81
pubmed: 26650973
J R Soc Med. 2008 May;101(5):222-5
pubmed: 18463276
PLoS One. 2012;7(8):e42421
pubmed: 22905130
J Psychoactive Drugs. 2019 Apr-Jun;51(2):135-145
pubmed: 30732540
Ann Intern Med. 2002 Jun 4;136(11):817-25
pubmed: 12044130
Behav Ther. 2007 Sep;38(3):234-46
pubmed: 17697849
Sci Rep. 2017 Nov 9;7(1):15201
pubmed: 29123145
Int J Drug Policy. 2008 Aug;19(4):297-303
pubmed: 18638702
Psychol Med. 1998 May;28(3):551-8
pubmed: 9626712
Psychopharmacology (Berl). 2020 Apr;237(4):1161-1169
pubmed: 31927605
Drug Alcohol Depend. 2010 Oct 1;111(3):257-61
pubmed: 20554400
J Consult Clin Psychol. 2002 Apr;70(2):275-87
pubmed: 11952186
J Nerv Ment Dis. 1996 Feb;184(2):86-94
pubmed: 8596116
Psychopharmacology (Berl). 2019 Feb;236(2):573-580
pubmed: 30406413
Front Hum Neurosci. 2016 Jun 14;10:269
pubmed: 27378878
J Psychoactive Drugs. 2015 Nov-Dec;47(5):351-9
pubmed: 26514589
Health Psychol. 1999 Sep;18(5):495-505
pubmed: 10519466
Biol Trace Elem Res. 2021 Mar;199(3):1179-1184
pubmed: 32504397
Sci Rep. 2020 Mar 5;10(1):4075
pubmed: 32139811
Psychiatry Res. 2018 Jun;264:334-339
pubmed: 29674223
PLoS One. 2019 Apr 23;14(4):e0214377
pubmed: 31013281
J Consult Clin Psychol. 2012 Jun;80(3):365-72
pubmed: 22409641
Psychopharmacology (Berl). 2016 Mar;233(5):823-9
pubmed: 26612618
Psychol Med. 2019 Mar;49(4):655-663
pubmed: 29903051
Curr Neuropharmacol. 2019;17(2):108-128
pubmed: 29366418
J Ethnopharmacol. 1999 Jun;65(3):243-56
pubmed: 10404423
Science. 2009 Feb 13;323(5916):934-7
pubmed: 19213917
J Pharmacol Exp Ther. 2003 Jul;306(1):73-83
pubmed: 12660312
PeerJ. 2018 Jun 1;6:e4903
pubmed: 29876148
Soc Sci Med. 2006 Mar;62(6):1486-97
pubmed: 16168541
Psychopharmacology (Berl). 2020 Apr;237(4):1171-1182
pubmed: 31938878
Braz J Psychiatry. 2015 Jan-Mar;37(1):13-20
pubmed: 25806551
Compr Psychiatry. 2016 Nov;71:95-105
pubmed: 27653781
Curr Opin Psychol. 2019 Aug;28:245-251
pubmed: 30908987
J Psychoactive Drugs. 2019 Jan-Mar;51(1):3-11
pubmed: 30582439
Med Sci Monit. 2008 Aug;14(8):SR15-22
pubmed: 18668010
Eur Neuropsychopharmacol. 2015 Apr;25(4):483-92
pubmed: 25637267
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683
J Clin Psychol. 2009 Jun;65(6):613-26
pubmed: 19267330

Auteurs

Debora Gonzalez (D)

International Center for Ethnobotanical Education, Research and Services (ICEERS), Barcelona, Spain.
PHI Association, Barcelona, Spain.
Fundación BeckleyMed, Barcelona, Spain.

Jordi Cantillo (J)

International Center for Ethnobotanical Education, Research and Services (ICEERS), Barcelona, Spain.

Irene Perez (I)

International Center for Ethnobotanical Education, Research and Services (ICEERS), Barcelona, Spain.

Maria Carvalho (M)

Catholic University of Portugal, Barcelona, Spain.

Adam Aronovich (A)

Medical Anthropology Research Center, Department of Anthropology, Philosophy and Social Work, University of Rovira I Virgili, Tarragona, Spain.

Magi Farre (M)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias I Pujol and Institut de Recerca Germans Trias I Pujol (IGTP), Barcelona, Spain.
Department of Pharmacology, Therapeutics and Toxicoloy, Universitat Autònoma de Barcelona, Barcelona, Spain.

Amanda Feilding (A)

Fundación BeckleyMed, Barcelona, Spain.
The Beckley Foundation, Oxford, United Kingdom.

Jordi E Obiols (JE)

Department of Clinical and Health Psychology, Faculty of Psychology, Autonomous University of Barcelona, Barcelona, Spain.

José Carlos Bouso (JC)

International Center for Ethnobotanical Education, Research and Services (ICEERS), Barcelona, Spain.
Medical Anthropology Research Center, Department of Anthropology, Philosophy and Social Work, University of Rovira I Virgili, Tarragona, Spain.
Department of Neurosciences and Behavior, Ribeirão Preto Medical School, University of São Paulo, Brazil.

Classifications MeSH